Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author holds a long position in BFLY.
← Back to Free Index

BFLY

Analysis as of: 2026-07-28
Butterfly Network, Inc.
Butterfly sells handheld ultrasound devices, cloud workflow software, and partner tools that bring medical imaging closer to the bedside and home.
ai hardware healthcare medical devices software
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Real Imaging Platform, Premium Valuation, Proof Still Needed
The upside case is a shift from selling handheld devices to monetizing a broader imaging workflow and partner ecosystem. The challenge is that the stock already prices in part of that transition, so execution must stay ahead of incumbent bundling and slower clinical adoption.

Analysis

Thesis
Butterfly can create a real 2x equity outcome by 2031 if it turns handheld ultrasound from a device sale into a regulated imaging network: more probes in more settings, better software attach, and repeatable embedded licensing. The nonlinear upside is real, but today’s premium valuation means execution has to outrun hardware bundling and prove the platform mix is durable.
Last Economy Alignment
AI should make ultrasound usable in many more care settings, and Butterfly owns the regulated device plus workflow layer. It benefits from cheaper cognition, but it is not a core compute bottleneck and still faces incumbent bundling risk.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
2.1x (from 5 most recent analyses)
Reasoning
The upside case is not a simple probe volume story. It depends on Butterfly proving that its chip platform, hospital workflow software, and partner channels can widen use cases faster than price pressure narrows hardware economics. I expect meaningful revenue growth but some valuation compression from today’s rich starting point, so the stock outcome is strong but not extreme.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
The device is real and the margin trend is improving, but the five-year upside needs three proof points: recurring enterprise workflow wins, commercially relevant embedded revenue, and repeatable home/community care adoption. If those stay niche, Butterfly remains a premium handheld device company and the valuation can compress faster than revenue grows.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.36
They own the handheld imaging device, the chip inside it, and some of the workflow around it, so cheaper AI can make ultrasound useful in many more places. The risk is that bigger imaging companies copy the handheld workflow or bundle it into broader contracts before Butterfly’s software and partner network become strong enough.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.06
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case